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Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes of cancer related
death. Despite the advances in understanding of the molecular pathogenesis, pancreatic cancer
remains a major unsolved health problem. Overall, the 5-year survival rate is less than 5%
demonstrating the insufficiency of current therapies.
Most cytotoxic therapies induce apoptosis and PDAC cells have evolved a plethora of molecular
mechanisms to assure survival. We will present anti-apoptotic strategies working at the level of the
death receptors, the mitochondria or involving the caspase inhibitors of the IAP family.
Furthermore, the survival function of the phosphotidylinositol-3' kinase (PI3K)/AKT- and NF-
kappaB-pathways are illustrated. A detailed molecular knowledge of the anti-apoptotic mechanisms
of PDAC cells will help to improve therapies for this dismal disease and therapeutic strategies
targeting the programmed cell death machinery are in early preclinical and clinical development.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most malignant tumor with an unfavorable prognosis.
More than 30.000 people develop pancreatic adenocarci-
noma each year in the United States, and almost all are
expected to die from the disease. Although the incidence
of pancreatic cancer is only about 10 in 105, it is the fourth
male and female leading cause of cancer-related death [1].
One reason for the poor prognosis of PDAC is the insen-
sitivity to most therapies like chemotherapy, radiotherapy
and immunotherapy. Therefore, surgical resection offers
at the moment the only potential chance for cure. The 5-
year survival rate of all patients is below 5%, and the
median survival time after diagnosis is 6 months. Further-
more, only about 20% of patients curative resected survive
longer than 5 years [2].
The hallmarks of nearly all cancers are deregulation of the
cell cycle machinery, self-sufficiency in growth signals,
insensitivity to growth inhibitory signals, evasion of apop-
tosis, tissue invasion, metastasis and sustained angiogen-
esis [2-4]. These characteristic changes can also be found
in PDAC and are detailed discussed in excellent reviews
from the groups of Depinho, Maitra, Hruban and Friess
[5-7]. The demonstration that the fraction of apoptotic
cells in PDAC predicts overall survival shows the impor-
tant contribution of the apoptotic machinery towards the
tumorbiology of PDAC [8].
Most chemotherapies act by induction of apoptosis.
Therefore, evasion of apoptosis is mainly responsible for
the insufficiency of current therapies [9]. Tumor cells use
multiple pathways to escape apoptosis [10]. This review
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PDAC.
Apoptosis – An overview
Apoptosis or programmed cell death is a central regulator
of normal tissue homeostasis. The physiological "cell sui-
cide" program is essential for the elimination of redun-
dant, damaged and infected cells [11,12]. Disturbed
apoptosis is involved in the pathogenesis of multiple dis-
eases, especially cancer.
Execution of apoptosis relies on a group of cysteine pro-
teases, the caspases [13]. Caspases are synthesized as pro-
forms and become activated by cleavage next to aspartate
residues. Since caspases cleave and activate each other, an
amplification mechanism through a protease cascade
exists, assuring proper execution of apoptotic cell death
[13]. In addition, caspases cleave numerous substrates,
like nuclear lamins, inhibitors of DNase or cytoskeletal
proteins, ultimatively leading to the typical morphologi-
cal alterations of apoptosis [13].
There are two alternative pathways to initiate apoptosis
and both finally activate the executioner caspases-3, -6
and -7 (figure 1):
The first pathway is called intrinsic or mitochondrial path-
way, because the mitochondria takes the key position by
initiating apoptosis. The exact mechanism of initiation by
different apoptotic stimuli is still not entirely clear, but
involves an imbalance of pro- and anti-apoptotic mem-
bers of the BCL-2 protein family [14]. This imbalance
finally leads to the activation of the pro-apoptotic BCL-2
family members BAX and/or BAK and the perturbance of
the integrity of the outer mitochondrial membrane [14].
This induces the release of cytochrom c and other apop-
totic regulators, like apoptosis-inducing factor (AIF),
Smac (second mitochondria-derived activator of apopto-
Pathways to ApoptosisFigure 1
Pathways to Apoptosis. The mitochondrial pathway is activated by BH3-only proteins, which sense cellular stress and inac-
tivate pro-survival BCL-2 family members. This leads to the permeabilization of the outer mitochondrial membrane and the 
release of cyctochrom C, Apaf-1 and caspase-9. The death receptor pathway is activated by the TNF family ligands. Caspase-8 
is activated by adaptor proteins including FADD. In PDAC cells, the death receptor pathway is linked to the mitochondria by 
the BH3-only protein Bid that is cleaved by caspase-8.Page 2 of 10
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(IAP)-binding protein with low PI), endonuclease G or
Omi/HtrA2 from the intermembraneous space of mito-
chondria [15]. In the cytosol, cytochrom c, APAF-1, ATP
and the initiator procaspase-9 are forming the apopto-
some multiprotein complex and activate the initiator cas-
pase-9. This induces the cleavage of the executioner
caspases, like caspase-3. Furthermore, the potent endog-
enous inhibitors of caspases, the inhibitor of apoptosis
proteins (IAPs) are neutralized by Smac/DIABOLO or
Omi/HtrA2 [16].
The second pathway is called the extrinsic pathway and is
mediated by different death receptors on the cell surface
[17-19]. These receptors are members of the tumor-necro-
sis factor (TNF) receptor superfamily, including the TNF-,
FAS-(APO-1, CD95) and TRAIL-(TNF-related apoptosis
inducing ligand) receptors. They share a common intrac-
ellular domain, which is called death domain. Activation
of the receptors after extracellular binding of the specific
ligands (TNF-α, FAS-L and TRAIL) initiates the recruit-
ment of FADD (FAS-associated death domain protein),
procaspase-8 and -10 to the death domain, which are
forming the DISC (death inducing signaling complex)
[20]. At the DISC, the initiator caspase-8 is activated. In
type I cells the activated initiator caspases are sufficient to
induce executioner caspases directly. In contrast type II
cells need the signal enhancing-effect of mitochondria to
induce apoptosis. Here, caspase-8 cleaves the pro-apop-
totic BH3-only BCL-2 family member BID, which translo-
cates to the mitochondrial membrane and induces the
release of apoptogenic factors from the mitochondria
[11]. Pancreatic carcinoma cells are type II cells [21,22].
The type I/II concept, is a good example of the crosstalk
between extrinsic and intrinsic apoptotic signaling and
demonstrates the complexity of apoptosis [23].
Apoptosis and Carcinogenesis of PDAC – an under-
investigated field
Apoptosis is a fundamental anti-neoplastic mechanism in
normal cells to prevent tumorigenesis. Nearly all neoplas-
tic changes during the development of a normal cell to a
cancer cell, like DNA-damage, oncogene activation or cell
cycle deregulation, are potent inducers of the pro-
grammed cell death pathway. Therefore, overcoming the
apoptotic failsafe is observed in many cancers as discussed
by Lowe, Cepero and Evan [24].
In accordance with the multi-step theory of carcinogene-
sis, the natural history of PDAC seems to gradually evolve
through precursor lesions, the so-called pancreatic
intraepithelial neoplasias (PanIN) 1 to 3 to invasiv PDAC
[2,5-7]. Whereas the progressive accumulation of genetic
somatic mutations, including mutations in the oncogene
K-RAS and the tumor suppressors CDKN2A, TP53,
SMAD4/DPC4 and BRCA2 are quite good understood, the
contribution of apoptosis to carcinogenesis of PDAC is
not well defined [3]. In PanIN 1 and 2 lesions, no apop-
totic cells could be detected, arguing for the contribution
of anti-apoptotic strategies early in the carcinogenesis of
PDAC [25]. These anti-apoptotic strategies most likely
enable cell survival under oncogenic stress conditions
[25]. Recently, two members of the IAP (inhibitors of
apoptosis) protein family, cIAP2 and Survivin were
shown to be early overexpressed during carcinogenesis of
PDAC. One anti-apoptotic function of the IAP family is
dependent on the inhibition of caspase activity [16]. Early
overexpression of cIAP2 was demonstrated in 30% of low-
grade PanIN lesions, 50% of high grade PanIN lesions and
85% of PDAC [26]. In addition to cIAP2, Survivin was
shown to be overexpressed already in PanIN1 lesions at
the mRNA and protein level [27]. Although the observed
overexpression of cIAP2 and Survivin, suggests early con-
tribution in tumorigenesis of PDAC, molecular pathways
engaged by these molecules in preneoplastic lesions of the
pancreas are unknown.
Death receptor signaling – blocked and abused
Many PDAC cells are characterized by a high IC50 for
death receptor mediated apoptosis, although they express
the corresponding receptors and the execution machinery
of apoptosis is intact [22,28-32]. PDAC cells have evolved
resistance mechanisms, which are especially working at
the death receptor level resulting in DISC insufficiency
[33].
The protein tyrosine phosphatase FAP-1 (FAS-associated
phosphatase-1) is overexpressed in PDAC and protects
pancreatic carcinoma cells from FAS-mediated apoptosis
by inhibiting the activation of caspase-8 [28,34]. It seems
that FAP-1 interferes with the translocation of CD95 to
the cell surface. This leads to a low receptor density on the
cell surface and to a disruption of receptor trimerization,
which is necessary to form the DISC. Furthermore a direct
inhibition of caspase-8 by FAP-1 is discussed [34]. The
resistance towards FAS-mediated apoptosis enables PDAC
cells to express simultaneously FASL, which might con-
tribute to escape the immunosurveillance. Compatibly,
expression of FASL was observed in 6/6 investigated
PDAC cell lines and co-culture of PDAC cells with T-cells
results in T-cell death in a FasL-dependent fashion [28].
Another potent inhibitor of caspase-8 activation is c-
FLIPL, which is a structural homologue of caspase-8, lack-
ing amino acid residues that are critical for caspase activ-
ity. c-FLIPL competes with procaspase-8 for binding to
FADD at the DISC [35,36]. Together with FAP-1, c-FlipL is
highly expressed in PDACs [35]. In addition to high c-
FLIPL expression, low amounts of FADD were shown toPage 3 of 10
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induced apoptosis in PDAC cells [32].
A further important mechanism to escape death-receptor
induced apoptosis is to favor pro-survival signaling after
triggering the death receptor. In PDAC cells, especially the
activation of NF-κB signaling (see below) contributes to
the resistance towards death receptor induced apoptosis
[21]. One factor involved in the induction of pro-survival
signaling is the death receptor adaptor TRAF2. TRAF2
belongs to the TRAF-family of adaptor proteins which are
involved in the signal transduction pathways of the TNF-
receptor family. Kalthoff's group observed TRAF2 overex-
pression in 94% of PDAC and the FASL-resistant cell lines
PancTuI, Panc89 and Panc1 [37]. Furthermore, ectopic
expression of TRAF2 in the FASL-sensitive pancreatic can-
cer cell line Colo357 confers resistance towards FAS-medi-
ated apoptosis, arguing for a pivotal role of TRAF2 in
mediating FAS resistance of pancreatic cancer cells. Mech-
anistically TRAF2 increases as well as basal as FAS-induced
NF-κB activity [37]. In addition, TRAF2 overexpression
increases the invasive properties of pancreatic cancer cells
by inducing the expression of proteolytic enzymes, like
matrix metalloproteinases 2 and 9 or the urokinase type
plasminogen activator (uPA) [37].
Another strategy to evade death-receptor apoptosis is the
overexpression of the decoy receptor 3 (DcR3). Decoy
receptors are members of the TNF-receptor superfamily,
but without an intact death domain. DcR3 competes with
FAS for FASL binding and therefore interferes with FAS
triggered apoptosis [35].
Since PDAC cells are type II cells, death receptor induced
apoptosis is also blocked at the level of the mitochondria
[22]. Furthermore, XIAP contributes to death receptor
resistance in PDAC cells [36,38].
BCL-2 family and PDAC – In favor for survival
At the level of the mitochondria deregulated expression of
members of the BCL-2 protein family causes apoptotic
resistance in PDAC [2,39,40]. This protein family consists
of two pro-apoptotic subgroups, the BAX-like group (BAX,
BAK, BOK) and the BH3-only subgroup (BAD, BIK, BID,
BIM, BMF, HRK, NOXA, PUMA) and the anti-apoptotic
subgroup (BCL-2, BCL-XL, BCL-W, MCL-1, A1)
[11,14,41]. In most cases, the mitochondrial cell death
pathway needs as well as the BAX-like group as the BH3-
only group. Here, BH3-only proteins act as sensors of cel-
lular stress, directly antagonizing anti-apoptotic BCL-2
members and activated BAX-like proteins are permeabiliz-
ing the outer mitochondrial membrane [14]. In contrast
to various other human tumors, expression of the proto-
typical pro-survival protein BCL-2 is normal or even
decreased in PDAC [39,40,42]. Faint BCL-2 expression
was detected especially in well-differentiated PDACs. Fur-
thermore, an inverse correlation between BCL-2 and p53
immunoreactivity was observed [40].
Resistance towards apoptosis at the mitochondrial level in
PDAC is conferred by at least two anti-apoptotic BCL-2
family members, BCL-XL and MCL-1. Both proteins are
known to be overexpressed [22,40,43,44]. BCL-XL and
MCL-1 are upregulated by MAPK signaling in PDAC cells
[43]. Whether MCL-1 is also induced by the NF-κB path-
way in pancreatic cancer cells, as it has been shown for
BCL-XL, is unknown at the moment [43,45]. In a murine
model of pancreatic cancer, the BCL-XL promoter was
shown to integrate the epidermal growth factor receptor
(EGF-R) signal. Here, EGF-R signaling contributes to the
activation of the transcription factors NF-κB and STAT3,
both activating the BCL-XL gene [45]. In line, inhibition of
both transcription factors is needed, to induce significant
apoptosis in this model [45].
Functionally, MCL-1 was recently linked to the integrative
stress response [46]. Therefore, high MCL-1 might protect
pancreatic cancer cells from hypoxia and oxidative stress
during tumorigenesis. From a therapeutically viewpoint,
dependency of survival of pancreatic cancer cells onto
MCL-1 has to be kept in mind, when molecular targeted
therapies, like ABT-737 treatment, are considered. ABT-
737 is a BAD homologous BH3-mimetic binding with
high affinity to BCL-XL, BCL-2 or BCL-w but not MCL-1
[47]. Hence, a molecular ABT-737 therapy is ineffective in
cells expressing significant amounts of MCL-1 [48]. This
applies also for pancreatic cancer cells, where only minor
apoptosis was observed after ABT-737 treatment. In con-
trast, ABT-737 induces distinct apoptosis of pancreatic
cancer cells after the depletion of MCL-1 [49]. A further
approach to sensitize towards ABT-737 is activation of
NOXA, a BH3-only selectively binding to and depleting
MCL-1. Enforced NOXA expression in murine embryonic
fibroblasts or the myelomonocytic cell line FDC-P1
increased sensitivity for ABT-737 up to 2000-fold [48].
Regulation of NOXA is not understood in pancreatic can-
cer, but strategies leading to NOXA activation are of value
if a molecular ABT-737 therapy is planned.
Little is known about the contribution of the pro-death
BCL-2 family members in PDAC. BAX expression is low-
ered in around 50% of PDACs [8,39]. In line with an
essential function in tumor cell killing, the median sur-
vival of BAX positive patients after pancreatic resection is
19 months versus 11 months of BAX negative patients [8].
Since BH3-only activation is a potential therapeutic strat-
egy, future studies have to address regulation of BH3-only
expression in PDAC in detail.Page 4 of 10
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The caspases are the central component of apoptosis. The
expression levels of caspases are more or less normal in
PDAC cells, but proper activation is impaired by potent
inhibitors, called IAPs (inhibitor of apoptosis proteins)
[29,33,50]. The IAP family, includes different members
like cIAP1, cIAP2, XIAP, NAIP, ML-IAP, ILP2, Livin, Apol-
lon and Survivin and one of the molecular mechanisms of
these proteins is to bind caspases and inhibit their activity
[51]. For PDAC the overexpression of cIAP2, XIAP and
Survivin has been demonstrated [26,27,52-54]. A recent
functional and systematic investigation of the IAP family
in PDAC conducted by Lemoine's group provide evidence
that cIAP2 and XIAP play key roles in anti-apoptotic sign-
aling. Downregulation of cIAP2 and XIAP by RNA inter-
ference in PDAC cell lines efficiently induced sensitivity
towards cisplatin, doxorubicin or paclitaxel [55]. Impor-
tantly, no synergism between downregulation of cIAP2
and XIAP was observed [55]. Furthermore, inhibition of
XIAP was shown to sensitize PDAC cells for death receptor
signaling, cytotoxic therapies and γ-irradiation [36,38,55-
59]. Since small molecule inhibitors exist, which target
XIAP function, the so-called XIAP antagonists (Xantags),
XIAP is a promising target for novel treatment strategies of
PDAC [36,59,60].
In addition, Survivin, the smallest member (16,5 kD) of
the IAP protein family contributes to anti-apoptotic sign-
aling in PDAC cells. Survivin is selectively expressed in
most human neoplasms including pancreatic cancer, but
not in normal adult tissue [27,61,62]. Survivin has been
implicated in control of cell division and inhibition of
apoptosis, by molecular mechanisms recently summa-
rized in an excellent review by Altieri [63]. The control of
cell division might explain the induction of apoptosis
observed after downregulation of Survivin expression in
PDAC cells, which was not overt after downregulation of
cIAP2 and XIAP [64-66]. In addition, downregulation of
Survivin by RNA interference sensitizes PDAC cells
towards TRAIL- and γ-irradiation-induced apoptosis
[65,66]. Interestingly, Survivin is expressed in a cell-cycle-
dependent manner in PDAC cells. Low expression was
observed at the RB-dependent restriction point in the late
G1-phase and this particular cell cycle phase was TRAIL-
sensitive [66]. Since cell cycle inhibitors are investigated
in clinical trials a combination therapy of G1-phase cell
cycle inhibition and death receptor activation might be a
feasible approach for the treatment of PDAC.
NF-κB – a key anti-apoptotic transcription factor in PDAC
NF-κB is a nuclear transcription factor, which is activated
by a variety of different stimuli. NF-κB controls different
biological processes like inflammation, cell cycle, apopto-
sis or epithelial to mesenchymal transition [67]. This tran-
scription factor binds DNA as a dimer, composed of the
NF-κB factors RelA (p65), RelB, c-Rel, NF-κB1 (p50/p105)
and NF-κB2 (p52/p100). Classical NF-κB (p50/p65
dimer) is usually kept in an inactive form in the cyto-
plasma by stable association with inhibitor proteins such
as IκBα or IκBβ. The IκBs are phosphorylated by a multi-
protein kinase complex, the Inhibitor of IκB kinase (IKK).
The IKK complex contains the two catalytical kinases IKKα
and IKKβ and the structural component IKKγ/NEMO
[68,69]. Activation of the IKK complex causes phosphor-
ylation of the IκBs, subsequents ubiquitination and pro-
teasomal degradation [68] (figure 2). This leads to the
liberation and nuclear translocation of classical NF-κB
and target gene activation. In addition to the canonical
NF-κB activation pathway, an alternative pathway
involves IKKα-dependent processing of NF-κB2 and
nuclear translocation of a p52/RelB dimer (figure 2). The
contribution of NF-κB to the tumorigenesis of various
cancers is well documented [70,71]. Also in PDAC, NF-κB
plays an important role [72-75]. In almost all PDAC cell
lines the IKK complex is activated, leading to the nuclear
translocation of NF-κB [76-78]. Interference with IKK
activity in PDAC cell lines leads to the induction of apop-
tosis and/or sensitization towards cytotoxic therapies
[77,78]. Although IKKα was shown to be overexpressed in
PDAC, downregulation of IKKα by RNA interference was
not accompanied by significant apoptosis [79,80].
Instead, IKKα was shown to promote cell cycle progres-
sion of PDAC cells by inducing transcription of the onco-
gene S-phase kinase associated protein 2 (SKP2) in a p52/
RelB-dependent fashion [80]. Therefore, anti-apoptotic
function of NF-κB signaling seems to be mediated by the
classical NF-κB pathway, but the contribution of canoni-
cal and non-canonical signaling to apoptosis resistance
has to be investigated in more detail. In line with activated
IKK, the NF-κB subunit RelA/p65 is nuclear translocated
in around 45 to 70% of pancreatic cancers [76,77,81].
Furthermore, nuclear RelA/p65 is a predictor for poor
patients survival and was linked to a higher expression of
NF-κB target genes, like BCL-XL [81]. Based on the broad
impact of NF-κB signaling towards the apoptotic machin-
ery, it is not surprising that inhibition of NF-κB activity
sensitizes pancreatic cancer cells to chemotherapeutic
agents and death-receptor mediated apoptosis [82-86].
Target genes of NF-κB in PDAC explaining the sensitizer
effect of NF-κB inhibition are BCL-XL and c-Flip [82,84-
86].
Although NF-κB is activated in PDAC, the signaling path-
ways leading to IKK activation in PDAC cells are not
entirely clear. Here the EGF-receptor-, PI3K-AKT- and K-
Ras-pathways were shown to contribute to NF-κB activity
[76,77]. Furthermore, NF-κB is modulated by several
other important signaling pathways in PDAC. For exam-
ple, Sarkar's group demonstrated that depleting Notch-1
expression in PDAC cells induces apoptosis and was cor-Page 5 of 10
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sion of the NF-κB target gene BCL-XL [87,88]. Moreover,
Notch-1/NF-κB signaling contributes to invasiveness of
PDAC cells [87]. Furthermore, casein kinase 2 (CK2)
maintains NF-κB activity and anti-apoptotic signaling in
PDAC cells [89]. A further modulator of NF-κB/RelA tran-
scriptional activity is the early response gene IEX-1, which
is involved in the regulation of apoptosis. In a recent
Representation of the two NF-κB signaling pathwaysFigure 2
Representation of the two NF-κB signaling pathways. Classical signaling (depicted left) is activated by TNFα, IL1β or 
LPS. Activation of canonical signaling depends on the IKK holocomplex (IKKα, IKKβ, IKKγ/NEMO). Activated IKK phosphor-
ylates IκBs, leading to the proteasomal degradation and subsequent nuclear translocation of classical NF-κB. An alternative sig-
naling pathway (depicted right) is activated by lymphotoxin, CD40L or BAFF. Signaling depends on IKKα and leads to the 
nuclear translocation of a p52/RelB dimer.Page 6 of 10
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the C-terminal activation domain of RelA and is involved
in inhibition of RelA-dependent transcriptional activity
and therefore negatively regulates NF-κB target genes, like
Bcl-XL, cIAP1 and cIAP2 [90]. This molecular observation
might explain the recent demonstration that IEX-1 expres-
sion is a significantly favorable factor for survival of
patients with PDAC [91].
The PI3K/AKT survival pathway
The phosphotidylinositol-3' kinase (PI3K)/AKT-pathway
is a pro-survival pathway in PDAC cells. This pathway is
activated by survival signals like growth factors, cytokines,
hormones and oncogenic Ras [92]. Activation of PI3K
leads to the phosphorylation of AKT/PKB. Besides the
growth promoting potential, activated AKT/PKB favors
survival via the direct regulation of apoptotic proteins,
like the BCL-2 members BAD and BCL-XL or caspase 9 [93-
96]. In addition, AKT modulates the activity of transcrip-
tion factors, like FOXO, NF-κB or c-myc. Schlieman et al.
has shown that the PI3K/AKT pathway is activated in
about 60% of pancreatic adenocarcinoma tissues and also
most pancreatic cancer cell lines display elevated levels of
activated AKT [97,98]. Although it was shown that PI3K/
AKT signaling modulates NF-κB and c-myc activity in
PDAC cells, the molecular activation of this pathway in
PDAC is not entirely clear [77,99,100]. Here, the contri-
bution of the tumor suppressor phosphatase and tensin
homolog deleted in chromosome ten (PTEN) has been
demonstrated [100]. Low expression of this natural antag-
onist of PI3K signaling was demonstrated in 75% of
PDACs [100]. In addition, a receptor tyrosin-kinase is
involved in PI3K activation, since the insulin receptor
substrate 1 (IRS-1) was shown to be an essential mediator
of PI3K activation in quiescent PDAC cells [101]. Further-
more, an unexpected pathway mediates the activation of
PI3K-AKT signaling in pancreatic cancer cells. This path-
way is regulated by the architectural transcription factor
HMGA1. HMGA1 is highly overexpressed in PDAC and
known to account for unrestrained proliferation of pan-
creatic cancer cells [102,103]. Recently, it was shown that
HMGA1 activates PI3K-AKT signaling in PDAC cells
[104,105]. By forming a complex with the transcription
factor C/EBPbeta, HMGA1 activates the insulin receptor
gene and the insulin receptor contributes to the activation
of PI3K-AKT signaling [106]. This pathway seems to medi-
ate therapeutic resistance, since HMGA1-mediated gem-
citabine resistance depends onto intact AKT signaling
[107].
Although we observed no overt apoptosis in PDAC cells
treated either with the PI3K inhibitor Ly294002 or by
interference with AKT1 expression using siRNAs (unpub-
lished data), inhibition of the PI3K/AKT signaling sensi-
tizes PDAC cells towards therapeutic induction of
apoptosis [97,108-111]. Since very high concentrations of
the PI3K inhibitor Ly294002 (up to 100 μM) were used in
many studies and contribution of the PI3K/AKT signaling
towards gemcitabine resistance were not detected in BxPc-
3, Capan-1 and PancTu-1 cells, the impact of PI3K/AKT
signaling for therapeutic resistance of PDAC cells has to be
clarified in more detail using functional genomics [112].
Conclusion
Deregulation of the apoptosis machinery and evasion of
apoptosis is a general mechanism in PDAC. Since nearly
every step during carcinogenesis activates apoptosis, the
development of anti-apoptotic strategies must be an early
and essential event. Contribution of molecules like cIAP2
or Survivin to early steps in the carcinogenesis of PDAC
should be investigated in relevant mouse models of PDAC
in the future. Also therapeutic resistance is mediated by
the profound deregulation of the apoptotic machinery in
PDAC cells. Detailed molecular knowledge of the anti-
apoptotic mechanisms of PDAC cells is essential for the
improvement of conventional chemotherapies ("sensi-
tizer strategies") and the development of new potent tar-
geted therapies. Hopefully, this will lead to an
improvement of the prognosis of this dismal disease.
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